Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
This historical lecture outlines the discovery and physiological relevance of circulating Na+, K+-ATPase inhibitors and atrial natriuretic peptide in the context of volume expansion and hypertension.
In view of the finding by Mathews et al1 that oneof the circulating Na+, K+-ATPase inhibitors inhumans is ouabain, I thought it would be useful to give a brief historical outline of the background to this subject and a tentative hypothesis that tries to explain how the concentration of such a substance comes to be raised in hypertension. Historical Outline In 1961 it was found that the natriuresis caused by acute volume expansion was due mainly to a change in the concentration of a circulating natriuretic sub-stance.2 About 10 years later it was noted that acute volume expansion was also accompanied by an in-crease in the ability of plasma to inhibit sodium transport34 and that this was due to an inhibition of Na+,K+-ATPase.5 It was automatically assumed that the increased natriuretic capacity of the plasma and its increased ability to inhibit sodium transport, both of which occurred with volume expansion, were due to a change in concentration of the same substance, which was named the natriuretic hormone. The atrial natriuretic peptide was discovered in 1981.6-7 To the surprise of many of us, the atrial natriuretic peptide had no effect on Na+,K+-ATPase. It was obvious, therefore, that the increased natri-uretic capacity of the plasma and its increased ability to inhibit Na+,K+-ATPase were not necessarily due to the same substance. It followed that the structure of the substance responsible for the volume-con-trolled Na+,K+-ATPase inhibition still needed to be determined. Furthermore, we began to pay attention to the well-established but not so well-recognized fact that in a normal animal the natriuretic effect of certain well-known exogenous Na+,K+-ATPase in-hibitors, such as ouabain and digoxin, is negligible. It was therefore ironic that at about this time the atrial natriuretic peptide (an unquestionably powerful short-acting natriuretic substance) was being closely scrutinized, and only slowly accepted, as a possible physiologically relevant natriuretic substance, while
No takes yet. Share an insight, caveat, or question.
H. E. de Wardener (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: